IDH1 and central nervous system cancer: Compared with other immune phenotypes, immune-L was found to have a higher proportion of IDH-mutant patients (Figures 8A, D); the immune-H phenotype seemed to have a higher proportion of recurrent glioma but a lower rate of primary patients (Figures 8B, E); more GBM samples existed in immune-H, and more LGG was associated with the immune-L phenotype (Figures 8C, F).